Therapeutic vaccines
to fight infectious diseases
and antibiotic resistance
ABOUT IGUANA
Iguana Biotechnology is a Munich-based Biotech Start-up founded in 2021 by Volker Wedershoven and Dr. Behnam Kalali.
Iguana’s core competence is the development of innovative, safe and efficient therapeutic vaccines against infectious diseases that address an unmet medical need and counteract the increasing resistance to antibiotic therapies, using a combination of intensive literature research, exchange with world-class experts and the use of the latest bioinformatics capabilities.
Pre-clinical results of the current core project ACT21, a therapeutic vaccine against Helicobacter pylori infection, are the best proof of success of Iguana´s scientific approach.
Iguana Founders:
Volker Wedershoven (CEO) and Dr. Behnam Kalali (CSO)
-
Our mission is to develop innovative, safe and efficient vaccines against infectious diseases that address an unmet medical need and counteract the increasing resistance to antibiotic therapies, using a combination of intensive literature research, exchange with world-class experts and the use of the latest bioinformatics capabilities.
-
Creating innovative solutions in the fight against infectious diseases.
-
We promote out-of-the-box thinking, teamwork, flat hierarchy and value the highest safety, quality and regulatory standards. We focus on integrity, trust and transparent communication with our owners, our team and our partners.